Deal Reached In Anixa Repriced-Stock Suit In Chancery
Anixa Biosciences Inc. has reached a proposed settlement instituting governance changes to resolve claims that its directors downpriced stock options held by insiders in 2017 while delaying a new patent award...To view the full article, register now.
Already a subscriber? Click here to view full article